Transient injection site reaction to alirocumab during immune system activation: a case series

BACKGROUND: Injection site reactions (ISRs) are known side effects of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor alirocumab. Transient ISR to alirocumab after a long phase of good tolerability have not been reported previously. CASE SUMMARY: A 55-year-old woman (Patient 1) and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bär, Sarah, Räber, Irene, Koskinas, Konstantinos C., Schlapbach, Christoph, Räber, Lorenz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113233/
https://www.ncbi.nlm.nih.gov/pubmed/35592747
http://dx.doi.org/10.1093/ehjcr/ytac187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113233/
https://www.ncbi.nlm.nih.gov/pubmed/35592747
http://dx.doi.org/10.1093/ehjcr/ytac187

Ejemplares similares